Tutor Perini Stock Trading at a Discount: Is It a Buy, Hold or Sell? — Positive
TPC Zacks Investment Research — October 14, 2025Tutor Perini Corporation TPC is currently trading at a discount compared with the Building Products - Heavy Construction industry peers and the broader Construction sector. The company's forward 12-month price-to-earnings (P/E) ratio is 14, which is below the industry average of 22.95 and the sector's valuation of 19.71.

Is NIKE's 20% Running Growth the Blueprint for Its Comeback? — Positive
NKE Zacks Investment Research — October 14, 2025NKE's 20% y/y rise in running signals its comeback as innovation and athlete-driven storytelling reignite consumer demand.

NVTS Stock Rises 90% in 3 Months: Time to Hold or Book Profits? — Positive
NVTS Zacks Investment Research — October 14, 2025Navitas Semiconductor skyrockets 90% in three months as it rides the AI data center boom and shifts to cost-efficient 8-inch GaN production.

Does Apogee Therapeutics Inc. (APGE) Have the Potential to Rally 72.52% as Wall Street Analysts Expect? — Positive
APGE Zacks Investment Research — October 14, 2025The consensus price target hints at a 72.5% upside potential for Apogee Therapeutics Inc. (APGE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Mizuho (MFG) Could Find a Support Soon, Here's Why You Should Buy the Stock Now — Positive
MFG Zacks Investment Research — October 14, 2025Mizuho (MFG) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Wall Street Analysts Believe Eupraxia Pharmaceuticals Inc. (EPRX) Could Rally 85.12%: Here's is How to Trade — Positive
EPRX Zacks Investment Research — October 14, 2025The consensus price target hints at an 85.1% upside potential for Eupraxia Pharmaceuticals Inc. (EPRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Princeton Bancorp (BPRN) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? — Neutral
BPRN Zacks Investment Research — October 14, 2025After losing some value lately, a hammer chart pattern has been formed for Princeton Bancorp (BPRN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

How Much Upside is Left in Exodus Movement, Inc. (EXOD)? Wall Street Analysts Think 98.53% — Positive
EXOD Zacks Investment Research — October 14, 2025The mean of analysts' price targets for Exodus Movement, Inc. (EXOD) points to a 98.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Fox (FOX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now — Positive
FOX Zacks Investment Research — October 14, 2025Fox (FOX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Fiverr (FVRR) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? — Positive
FVRR Zacks Investment Research — October 14, 2025Fiverr (FVRR) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Wall Street Analysts Think Day One Biopharmaceuticals (DAWN) Could Surge 241.59%: Read This Before Placing a Bet — Positive
DAWN Zacks Investment Research — October 14, 2025The mean of analysts' price targets for Day One Biopharmaceuticals (DAWN) points to a 241.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Does Byrna Technologies (BYRN) Have the Potential to Rally 65.23% as Wall Street Analysts Expect? — Positive
BYRN Zacks Investment Research — October 14, 2025The consensus price target hints at a 65.2% upside potential for Byrna Technologies (BYRN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Predict a 42.77% Upside in DarioHealth (DRIO): Here's What You Should Know — Positive
DRIO Zacks Investment Research — October 14, 2025The average of price targets set by Wall Street analysts indicates a potential upside of 42.8% in DarioHealth (DRIO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Predict a 36.47% Upside in Select Medical (SEM): Here's What You Should Know — Positive
SEM Zacks Investment Research — October 14, 2025The mean of analysts' price targets for Select Medical (SEM) points to a 36.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Here's Why Bank of Marin (BMRC) Looks Ripe for Bottom Fishing — Neutral
BMRC Zacks Investment Research — October 14, 2025After losing some value lately, a hammer chart pattern has been formed for Bank of Marin (BMRC), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Wall Street Analysts Believe Mobileye (MBLY) Could Rally 25.86%: Here's is How to Trade — Positive
MBLY Zacks Investment Research — October 14, 2025The average of price targets set by Wall Street analysts indicates a potential upside of 25.9% in Mobileye (MBLY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Predict a 30.28% Upside in Kodiak Gas (KGS): Here's What You Should Know — Positive
KGS Zacks Investment Research — October 14, 2025The average of price targets set by Wall Street analysts indicates a potential upside of 30.3% in Kodiak Gas (KGS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Does Kamada (KMDA) Have the Potential to Rally 114.39% as Wall Street Analysts Expect? — Positive
KMDA Zacks Investment Research — October 14, 2025The mean of analysts' price targets for Kamada (KMDA) points to an 114.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Think Kiniksa Pharmaceuticals International, plc (KNSA) Could Surge 29.3%: Read This Before Placing a Bet — Positive
KNSA Zacks Investment Research — October 14, 2025The mean of analysts' price targets for Kiniksa Pharmaceuticals International, plc (KNSA) points to a 29.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Believe Relay Therapeutics (RLAY) Could Rally 116.91%: Here's is How to Trade — Positive
RLAY Zacks Investment Research — October 14, 2025The mean of analysts' price targets for Relay Therapeutics (RLAY) points to an 116.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
